AVANOS MEDICAL INC (AVNS)
Health Care · Medical devices - specialty nutrition and pain management · NYSE
Avanos Medical delivers non-opioid pain management and specialized nutrition feeding devices to hospitals and home care providers, reducing opioid dependency and supporting nutritional therapy across patient recovery pathways.
What AVANOS MEDICAL INC does
Avanos Medical is a medical technology company that develops, manufactures, and markets clinical devices across two main segments: Specialty Nutrition Systems (enteral feeding, neonatal solutions) and Pain Management and Recovery (surgical pain pumps, radiofrequency ablation, cold and compression therapy). The company operates manufacturing facilities in the United States, Mexico, and Canada, and sells its products globally to healthcare providers and patients seeking alternatives to opioids and nutritional support solutions.
Themes: enteral nutrition / feeding, neonatal solutions, non-opioid pain management, surgical pain and recovery, radiofrequency ablation (RFA), chronic pain treatment
Fundamentals
- Price$24.99 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return+123.9% 2025-08-21 close $11.16 → 2026-08-21 close $24.99
- P/En/a negative earnings
- Net margin-10.4% as of 2026-08-24
- Gross margin+50.0% as of 2026-08-24
- ROE-9.6% as of 2026-08-24
- Debt / equity0.13 as of 2026-08-24
- Revenue growth (YoY)+3.9% as of 2026-08-24
- Revenue CAGR (3y)+0.8% SEC XBRL
- Beta-0.13 as of 2026-08-24
- Last reported earnings2026-05-05 SEC EDGAR Form 8-K (Item 2.02)
How AVNS compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AVANOS MEDICAL INC looks technically
AVANOS MEDICAL INC (AVNS) is trading 38.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 134 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 24 trading days ago. It is 2.0% below its 52-week high (its highest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 38.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +38.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.96 | $24.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.99 | $17.99 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 81 calendar days ago — the swings before that are what the structure reading is measured on | 81 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 14.27. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 134 trading days ago — a "golden cross", a bullish long-term signal | 134 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.8 |
Momentum
2
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.4 |
|---|---|---|
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 60 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.49 | $25.49 |
|---|---|---|
| From the 52-week high | it is 2.0% below its 52-week high (its highest price of the past year) | -2.0% |
| Above the 52-week low | it is 137.8% above its 52-week low (its lowest price of the past year) | +137.8% |
| Below the 52-week high | it is 2.0% below its highest point of the past year | 2.0% |
| Since a 20-day breakout | it made a new 20-day high about 24 trading days ago | 24 sessions |
| Since a 55-day breakout | it made a new 55-day high about 54 trading days ago | 54 sessions |
| All-time high | its highest closing price on record is $72.96 (set on 2018-09-05) | $72.96 |
| Given back of the 52-week move | over the past year its closes ranged ($10.66 to $25.05), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.70 to $16.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.4% |
| From the all-time high | it is 65.7% below its all-time high | -65.8% |
| Nearest price level | it is trading 1.2% above a support level at $24.68 — a price it turned at 8 times since 2024-09-04, most recently on 2026-07-01. Since 2024-08-21 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $9.30 (set on 2025-08-05) | $9.30 |
| Above the all-time low | it is 168.6% above its all-time low | +168.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0164 between its high and its low — about 0.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0164 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.99 and $24.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.99 – $24.99 – $24.99 |
| Typical daily range (% of price) | its price moves about 0.1% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.1% |
| Stretch from the 200-day average | it is trading 426.0 daily ranges above its 200-day average price (38.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.1% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 426.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 0% of its 30-day average | 0.00× |
|---|
Price gaps
1
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.3 percentage points (the stock gained 0.0% while the market gained 2.3%) | -2.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.9 percentage points (the stock gained 1.2% while the market gained 3.1%) | -1.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 50.6 percentage points (the stock gained 61.6% while the market gained 11.1%) | +50.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 103.4 percentage points (the stock gained 123.9% while the market gained 20.5%) | +103.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 8 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 8 |
|---|---|---|
| Bearish technical signals | 1 of the 8 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 8 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.5% of the share price, which is taken to mean a barrier that gives way easily. | +0.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $21.80 — a volume-weighted average of daily closes over 136 sessions, not a true tick-by-tick VWAP. | +14.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-05-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $24.86 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | +0.5% |
Price levels it has turned at before
AVNS last closed at $24.99 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.68 | Support | 1.2% below the last close | turned there 8 times · 2024-09-04 to 2026-07-01 |
| $25.43 | Resistance | 1.7% above the last close | turned there twice · 2024-09-20 to 2026-06-01 |
| $17.59 | Support | 29.6% below the last close | turned there twice · 2024-11-20 to 2025-01-30 |
| $15.60 | Support | 37.6% below the last close | turned there three times · 2025-01-23 to 2026-02-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $14.27.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $19.26 and $22.55 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $25.49.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Least volatile (2% or less typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst EPS estimate for AVNS
- Consensus EPS estimate$0.16 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Pending merger with American Industrial Partners could restrict business opportunities and there is uncertainty about completing it on anticipated terms","Concentration of manufacturing operations in Mexico creates supply chain vulnerability and exposure to tariffs, currency fluctuations, and geopolitical tensions","Reductions or eliminations of reimbursements from government healthcare programs or private insurers could adversely affect demand and pricing for products"]
What changed in the latest 10-Q
AI-assisted comparison of AVNS's 10-Q filed 2026-05-05 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Pending Merger section added describing April 13, 2026 Merger Agreement with American Industrial Partners affiliates at $25.00 per share
- Reference to Form 8-K dated April 14, 2026 regarding Merger Agreement
- Reference to Note 14 'Subsequent Event' for merger details
- Tariffs section added discussing impact of U.S. tariffs on operations in Mexico, Canada, and sourcing from China/Mexico
- Statement that tariffs have increased costs and disrupted supply chains
- Description of mitigation actions taken for tariffs including cost containment, pricing actions, and supply chain adjustments
- Removed:
- Goodwill Impairment section removed (detailed $77.0 million impairment to PM&R reporting unit recorded in Q2 2025)
- Transformation Process section removed (initial restructuring from January 2023)
- Sale of HA Assets section removed (July 31, 2025 sale to Channel-Markers Medical)
- Discontinued Operations section removed (October 2, 2023 RH Divestiture details)
- Reworded:
- Form 10-K reference changed from 'year ended December 31, 2024' to 'year ended December 31, 2025'
- Topics list reorganized: removed Goodwill Impairment, Sale of HA Assets, and Discontinued Operations; added Pending Merger; reordered remaining items
- Post-RH Divestiture Plan section revised: timeline language changed from 'expected to be substantially complete by end of 2025' to 'expected to run through 2026'
- Restructuring costs reporting: Q1 2026 costs of $1.8 million compared to Q1 2025 costs of $3.1 million (changed from Q3 2025 vs Q3 2024 comparison in older filing)
- CEO appointment timing clarified: 'recent appointment' in older filing changed to 'appointment of our new Chief Executive Officer in April 2025' in newer filing
- Business Acquisition section: shortened description of Nexus merger outcome from 'with Nexus surviving the merger as a wholly owned subsidiary of the Company (the "Nexus Acquisition")' to 'with Nexus surviving the merger as a wholly owned subsidiary of the Company'
- Note reference changed from Note 4 to Note 3 for Business Acquisition details
- Notes:
- Older filing text appears truncated at end of Discontinued Operations section; comparison based on available text
- Changes reflect comparison of Q1 2026 10-Q (newer) versus Q3 2025 10-Q (older), spanning different reporting periods
Risk Factors
- Added:
- Added forward-looking statement risk factor: 'our inability to complete our pending merger with certain affiliates of American Industrial Partners on the anticipated terms, or at all' (filed 2026-05-05)
- Added forward-looking statement risk factor: 'potential adverse effects on our business and operations due to the pendency of the merger' (filed 2026-05-05)
- Added forward-looking statement risk factor: 'provisions in the Agreement and Plan of Merger that may restrict our ability to pursue new opportunities or take other actions that might be beneficial to our business' (filed 2026-05-05)
- Reworded:
- Updated Form 10-K reference year from 'December 31, 2024' (filed 2025-11-05) to 'December 31, 2025' (filed 2026-05-05) in forward-looking statements disclosure
- Reordered forward-looking risk factors list: merger-related items added after 'fluctuations in global equity and fixed-income markets' and before 'our ability to successfully execute on or achieve the expected benefits of our restructuring initiatives' (filed 2026-05-05 vs 2025-11-05)
- Notes:
- Newer filing contains only partial financial statements (three months ended March 31, 2026); older filing contains nine-month comparative data (nine months ended September 30, 2025), making financial comparison limited to different reporting periods
- Table of Contents page numbering differs between filings (Item 1A at page 31 in newer vs page 34 in older)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AVNS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AVNS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,686,513
- Reported value $135,708,058
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AVNS had 1,751,047 shares of reported short interest as of the 2026-07-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVNS had 3.74% of its shares outstanding sold short as of the 2026-07-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.35 days to cover at the same settlement.
- Reported short interest (shares) 1,751,047
- Short interest (% of shares outstanding) 3.74%
- Prior settlement (shares) 1,774,282
- Reported change -1.31%
- Days to cover (reported) 2.35
Reported to FINRA as of the 2026-07-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fresenius Kabi
- Nestlé Health Science
- B. Braun
- Medtronic
- Halyard Health
- Cardinal Health
- Zimmer Biomet
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVNS vs…
Frequently asked questions
What does AVANOS MEDICAL INC (AVNS) do?
Avanos Medical is a medical technology company that develops, manufactures, and markets clinical devices across two main segments: Specialty Nutrition Systems (enteral feeding, neonatal solutions) and Pain Management and Recovery (surgical pain pumps, radiofrequency ablation, cold and compression therapy).
What sector is AVANOS MEDICAL INC (AVNS) in?
AVANOS MEDICAL INC (AVNS) is classified in the Health Care sector. Its industry is Medical devices - specialty nutrition and pain management. It trades on NYSE.
Who are AVANOS MEDICAL INC's (AVNS) competitors?
Notable peers of AVANOS MEDICAL INC (AVNS) include Fresenius Kabi, Nestlé Health Science, B. Braun, Medtronic and Halyard Health. This peer set is informational only — not financial advice.
Is AVANOS MEDICAL INC (AVNS) overbought or oversold right now?
AVANOS MEDICAL INC (AVNS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVNS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.